Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions
From The IMID Forum by The Immune-Mediated Inflammatory Disease Forum
March 26, 2026 · 10 min
About this episode
Professor Iain McInnes reviews the malignancy risk in RA patients and the evolution of JAKi prescriptions since 2015.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.
People in this episode
Host: Professor Iain McInnes
Topics covered
- rheumatoid arthritis
- malignancy risk
- JAK inhibitors
- b/tsDMARDS
- international collaboration
- prescription evolution
Keywords
- rheumatoid arthritis
- malignancy risk
- JAK inhibitors
- b/tsDMARDS
- prescription trends
- international registers
Mentioned in this episode
Organizations: The Immune-Mediated Inflammatory Disease Forum
Products: b/tsDMARDS, JAKi
Books & works: Discussing RA
More episodes of The IMID Forum
- EULAR 2026 Review Podcast · June 12, 2026 · 40 min
- EULAR 2026 Day 4 Highlights Podcast · June 6, 2026 · 5 min
- EULAR 2026 Day 3 Highlights Podcast · June 5, 2026 · 3 min
- EULAR 2026 Day 2 Highlights Podcast · June 4, 2026 · 6 min
- EULAR 2025 Day 1 Highlights Podcast · June 3, 2026 · 6 min
- Discussing RA: Comparative outcomes with upadacitinib in RA · May 28, 2026 · 9 min
Explore listener stats, chart rankings, contacts and more on the The IMID Forum podcast page.